佩瑞索利单抗治疗类风湿关节炎的细胞与蛋白质组学变化:2a期随机试验事后分析
该事后分析基于一项2a期双盲随机安慰剂对照试验,98例中重度类风湿关节炎患者随机接受佩瑞索利单抗700mg、300mg或安慰剂静脉给药。结果显示佩瑞索利单抗暴露呈剂量比例增加,终末半衰期约9天,两个剂量组循环CD4效应记忆T细胞PD-1受体占有率均超过90%;
要点
- 佩瑞索利单抗300mg和700mg组循环CD4效应记忆T细胞PD-1受体占有率均超过90%。
- 佩瑞索利单抗组中性粒细胞计数下降超过10%,RNA测序结果一致。
核心结论
- 佩瑞索利单抗通过PD-1激动作用减少外周PD-1高表达CD4 T细胞和中性粒细胞,并使多种炎症相关分子通路正常化。
研究设计与样本
- 2a期双盲随机安慰剂对照试验事后分析,在欧洲、墨西哥和美国26个中心进行。
- 98例成人中重度类风湿关节炎患者按2:1:1随机接受佩瑞索利单抗700mg(n=49)、300mg(n=25)或安慰剂(n=24)静脉给药,每4周一次。
- 事后分析评估药代动力学、PD-1占有率及从基线至第14周(药代动力学至第36周)的细胞和分子生物标志物变化。
主要发现
- 佩瑞索利单抗暴露呈剂量比例增加,终末半衰期约9天。
- 两个剂量组循环CD4效应记忆T细胞PD-1受体占有率均超过90%。
- PD-1低表达T细胞及其他主要细胞类型未见有意义差异。
- 佩瑞索利单抗组中性粒细胞计数下降超过10%,RNA测序结果一致。
关键数值与推荐
- 佩瑞索利单抗300mg和700mg组循环CD4效应记忆T细胞PD-1受体占有率均超过90%。
- 佩瑞索利单抗组中性粒细胞计数下降超过10%。
临床怎么用
- 佩瑞索利单抗可减少外周PD-1高表达CD4 T细胞和中性粒细胞,并下调IL-6等炎症通路。
- 该药后续2b期剂量范围研究(NCT05516758)后已停止进一步开发。
局限性
- 该分析为2a期试验的事后分析,样本量有限(共98例)。
- 研究未纳入有类风湿关节炎亲身经历者参与设计或实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peresolimab, a monoclonal antibody that stimulates human PD-1, demonstrated superiority over placebo in a phase 2a trial assessing Disease Activity Score in 28 joints using C-reactive protein over 12 weeks in adults with moderate-to-severe rheumatoid arthritis. In this post-hoc analysis, we report the pharmacokinetic and exploratory biomarker results from this trial. METHODS: We did a phase 2a double-blind, randomised, placebo-controlled trial across 26 centres in Europe, Mexico, and the USA. Eligible participants were aged 18 years or older, with a diagnosis of adult-onset rheumatoid arthritis and moderate-to-severe disease activity. Patients were randomly assigned (2:1:1) to receive peresolimab 700 mg, peresolimab 300 mg, or placebo intravenously once every 4 weeks during the 14-week placebo-controlled period. This post-hoc analysis assessed peresolimab pharmacokinetics, PD-1 coverage with peresolimab, and cellular and molecular biomarker changes from baseline to week 14 (or to week 36 for pharmacokinetics). Blood and serum samples were collected from patients who received peresolimab or placebo and from control participants without a diagnosis of rheumatoid arthritis as a baseline comparison. Cellular changes were assessed using standard flow cytometry and molecular changes were assessed with Olink proteomics and RNA sequencing. People with lived experience of rheumatoid arthritis were not involved in the design or conduct of the study. The phase 2a trial was registered with ClinicalTrials.gov (NCT04634253) and is completed. FINDINGS: Between Jan 4, 2021, and Jan 10, 2022, 172 patients were screened for eligibility of whom 98 (82 [84%] female and 16 [16%] male; mean age 51·7 [SD 12·6]) were randomly assigned to receive peresolimab 700 mg (n=49), peresolimab 300 mg (n=25), or placebo (n=24). Across the doses studied, peresolimab showed a dose-proportional increase in exposure (terminal half-life approximately 9 days); both peresolimab 300 mg and 700 mg groups had greater than 90% receptor occupancy on circulating CD4 effector memory T cells over the treatment period. From baseline to 12 weeks, PD-1 high-expressing CD4 T cell count for the peresolimab group decreased between -52·2% and -57·1%. No meaningful differences were seen for PD-1 low-expressing T cells or any other major cell types or subsets. Neutrophil count decreased by more than 10% in the peresolimab group, corroborated by RNA-sequencing results. Proteomic data analysis identified multiple pathways showing differences between peresolimab and placebo starting at week 8, including treatment-induced down-modulation of cytokines and chemokines in interleukin signalling pathways, including IL-6. INTERPRETATION: PD-1 agonism with peresolimab resulted in reduction of peripheral PD-1 high-expressing CD4 T cells and neutrophils, as well as normalisation of numerous molecular pathways associated with inflammation in patients with moderate-to-severe rheumatoid arthritis. Peresolimab treatment was evaluated in a subsequent phase 2b dose ranging study (NCT05516758), after which further development of peresolimab was discontinued. FUNDING: Eli Lilly and Company.
引用
- Benschop RJ, Tuttle JL, Emery P, et al. Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial. Lancet Rheumatol. 2026. PMID: 42810367. doi:10.1016/S2665-9913(26)00218-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。